Jain, Rohit

Publications

Sort by

Co-Author Network

selected publications

A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nature medicine. 2024 Academic Article GET IT
A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder. Clinical genitourinary cancer. 2024 Academic Article GET IT
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Academic Article GET IT
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors. JCO clinical cancer informatics. 2024 Academic Article GET IT
Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clinical genitourinary cancer. 2024 Academic Article GET IT
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics. JCO precision oncology. 2024 Academic Article GET IT
Times cited: 2
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Annals of oncology : official journal of the European Society for Medical Oncology. 2024 Academic Article GET IT
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy. European urology oncology. 2023 Academic Article GET IT
Times cited: 3
Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urologic oncology. 2023 Academic Article GET IT
Times cited: 1
A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Times cited: 5
Antibody-Drug Conjugates in the Treatment of Urothelial Cancer. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2023 Review GET IT
Times cited: 3
Immune Checkpoint Inhibitor Toxicity Management in Non-muscle-invasive Bladder Cancer: What Urologists Need To Know. European urology focus. 2023 Review GET IT
Times cited: 2
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nature reviews. Urology. 2023 Review GET IT
Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma. Urologic oncology. 2023 Academic Article GET IT
Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension. Current oncology (Toronto, Ont.). 2023 Academic Article GET IT
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. Expert opinion on emerging drugs. 2023 Review GET IT
A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers. 2022 Academic Article GET IT
Times cited: 8
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA oncology. 2022 Academic Article GET IT
Times cited: 64
Yttrium-90 Radioembolization for Liver-Dominant Metastatic Prostate Cancer: A Case Series. Journal of vascular and interventional radiology : JVIR. 2022 Academic Article GET IT
Times cited: 2
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma. Cancer immunology, immunotherapy : CII. 2022 Academic Article GET IT
Times cited: 5
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urologic oncology. 2022 Academic Article GET IT
Times cited: 3
Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA network open. 2022 Academic Article GET IT
Times cited: 19
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. Clinical genitourinary cancer. 2022 Academic Article GET IT
Times cited: 9
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. BJUI compass. 2021 Academic Article GET IT
Times cited: 7
Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. Urologic oncology. 2021 Academic Article GET IT
Times cited: 1
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. Clinical genitourinary cancer. 2021 Academic Article GET IT
Times cited: 5
Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6. European urology. 2021 Letter GET IT
Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study. Cardiovascular and interventional radiology. 2021 Academic Article GET IT
Times cited: 5
The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Frontiers in immunology. 2021 Review GET IT
Times cited: 16
Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. The Journal of urology. 2021 Academic Article GET IT
Times cited: 18
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU international. 2021 Academic Article GET IT
Times cited: 14
Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA network open. 2021 Academic Article GET IT
Times cited: 26
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 334
Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma. 2021 GET IT
Times cited: 1
Robotic radical nephroureterectomy in a patient with situs inversus totalis. 2021 GET IT
Times cited: 3
Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. Clinical genitourinary cancer. 2021 Academic Article GET IT
Times cited: 13
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. European urology. 2021 Academic Article GET IT
Times cited: 2
Should Upper-tract Urothelial Carcinoma and Bladder Carcinoma Be Treated the Same or Different?. European urology oncology. 2021 Editorial Article GET IT
Times cited: 3
Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab. 2020 GET IT
Times cited: 35
Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin. Cancer management and research. 2020 Review GET IT
Times cited: 12
Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate cancer and prostatic diseases. 2020 Academic Article GET IT
Times cited: 22
Neoadjuvant therapy for muscle-invasive bladder cancer. Expert review of anticancer therapy. 2020 Review GET IT
Times cited: 12
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical genitourinary cancer. 2020 Academic Article GET IT
Times cited: 5
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical genitourinary cancer. 2020 Academic Article GET IT
Times cited: 8
Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability. 2020 GET IT
Times cited: 13
Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?. BJU international. 2019 Editorial Article GET IT
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. Cells. 2019 Review GET IT
Times cited: 40
Correction to: Immunotherapy Advances in Urothelial Carcinoma. 2019 GET IT
Important caveats of KEYNOTE-045: relevance of these findings in the current and future therapeutic paradigm. Annals of translational medicine. 2019 Editorial Article GET IT
Immunotherapy Advances in Urothelial Carcinoma. Current treatment options in oncology. 2018 Review GET IT
Times cited: 5
Second-line systemic therapy in metastatic renal-cell carcinoma: A review. Urologic oncology. 2017 Review GET IT
Times cited: 12
Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Laboratory investigation; a journal of technical methods and pathology. 2012 Academic Article GET IT
Times cited: 24
Extrathoracic metastases of thymic origin: a review of 35 cases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2011 Academic Article GET IT
Times cited: 51
Atypical ductal hyperplasia: interobserver and intraobserver variability. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2011 Academic Article GET IT
Times cited: 97
FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast cancer research and treatment. 2011 Academic Article GET IT
Times cited: 99
High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology. 2011 Academic Article GET IT
Times cited: 59
Personalized medicine: the road ahead. Clinical breast cancer. 2011 Review GET IT
Times cited: 40
WHO types A and AB thymomas: not always benign. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2010 Academic Article GET IT
Times cited: 39
Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. Journal of clinical pathology. 2010 Academic Article GET IT
Times cited: 9
Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2009 Academic Article GET IT
Times cited: 44
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast cancer research and treatment. 2009 Academic Article GET IT
Times cited: 156

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Winn CDA Contact for Dr. Rohit Jain awarded by Bristol-Myers Squibb Company Principal Investigator 2024 - 2026

Winn CDA Contact for Dr. Rohit Jain awarded by Bristol-Myers Squibb Company Principal Investigator Subaward 2024 - 2026

more ...

less ...

Background

education and training

M.D., University of the State of New York 24
M.P.H., Indiana University School of Medicine 2010
M.B.,B.S., Topiwala Medical College, University of Bombay (India) 2007

Contact

full name

Rohit Jain

primary email

rkj4003@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Rohit Jain Associate Professor of Medicine (Pending Appointment at Rank)

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage